IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 12795 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »  Article in PDF (144 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)

 
In This Article
 »  References

 Article Access Statistics
    Viewed2642    
    Printed136    
    Emailed0    
    PDF Downloaded91    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO EDITOR
Year : 2011  |  Volume : 43  |  Issue : 1  |  Page : 95
 

Authors' reply


Department of Pharmacology, Government Medical College, Jagdalpur, Chhattisgarh, India

Date of Web Publication15-Jan-2011

Correspondence Address:
Harminder Singh
Department of Pharmacology, Government Medical College, Jagdalpur (C.G) - 494 001, Chhattisgarh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21455442

Rights and PermissionsRights and Permissions



How to cite this article:
Singh H, Dulhani N, Kumar BN, Singh P, Tiwari P. Authors' reply. Indian J Pharmacol 2011;43:95

How to cite this URL:
Singh H, Dulhani N, Kumar BN, Singh P, Tiwari P. Authors' reply. Indian J Pharmacol [serial online] 2011 [cited 2023 Sep 28];43:95. Available from: https://www.ijp-online.com/text.asp?2011/43/1/95/75690


Sir,

This is with reference to the comments on our article. [1],[2] Respected reader has raised his/her concern on the criteria that merited its publication. In support of our published article, we humbly put forward the following:

  1. The established drug efficacy studies/concepts need repetition in different gene pool/geographical area to verify the optimal results in diverse situations. [3],[4] The repeated validation in dissimilar condition makes the established fact more relevant.
  2. Apart from the efficacy of hydroxyurea, we also had our concern about safety aspects throughout the study period. [2]
  3. Even the negative results are welcome in scientific community and some of the journals are fanatical for this job. We have conducted a scientifically sound, ethically approved, prospective study in sickle cell disease endemic tribal area which itself holds some logical merit to make a place in indexed journal. [5]
  4. Our main objective was to recommend a wider adoption of hydroxyurea for treatment in areas of high prevalence of sickle cell disease, which is still lacking. The Indian Journal of Pharmacology has shown a full accountability and scientific conclusion to decide on this study in their much valued journal.


 
 » References Top

1.Beedimani R. The novelty of research article: Whose responsibility is it? Indian J Pharmacol 2011;43:94-5.  Back to cited text no. 1
  Medknow Journal  
2.Singh H, Dulhani N, Kumar BN, Singh P, Tiwari P. Effective control of sickle cell disease with hydroxyurea therapy. Indian J Pharmacol 2010;42:32-5.  Back to cited text no. 2
[PUBMED]  Medknow Journal  
3.Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-1.   Back to cited text no. 3
    
4.Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr 1996;129:559-65.   Back to cited text no. 4
[PUBMED]  [FULLTEXT]  
5.A biannual newsletter of regional medical research centre for tribals, Jabalpur, April 2005. Available from: http://www.icmr.nic.in/000519/Newsletter_vol2No1.pdf. [last accessed on 2009].  Back to cited text no. 5
    




 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow